Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 5 f g
Lee H et al. (2020)
|
Xla Wt + chrd.1 MO
NF32 (in situ hybridization)
|
|
|
|
Fig. 5 f g
Lee H et al. (2020)
|
Xla Wt + rspo2 MO
NF32 (in situ hybridization)
|
|
|
|
Fig.6.S1.E
Chen M et al. (2020)
|
Xla Wt + tmem79 MO
NF16 (in situ hybridization)
|
|
|
|
Fig. 3B, row1, col3
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 18 (in situ hybridization)
|
|
|
|
Fig. 3. supp1 D
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 18 (in situ hybridization)
|
|
|
|
Fig. 3B, row1, col4
Chang LS et al. (2020)
|
Xtr WT + wnt8a
NF 18 (in situ hybridization)
|
|
|
|
Fig. 3. supp1 D
Chang LS et al. (2020)
|
Xtr WT + wnt8a
NF 18 (in situ hybridization)
|
|
|
|
Fig. 4 C lane 3
Lichtig H et al. (2020)
|
Xla + asxl3 MO
NF16 (RT-PCR)
|
|
|
|
Fig. 4 A lane 5
Lichtig H et al. (2020)
|
Xla Wt + asxl3 MO + animal cap amputation
NF16 (RT-PCR)
|
|
|
|
Fig.8.f,h
Pai VP et al. (2018)
|
Xla Wt + Nicotine
NF25 (in situ hybridization)
|
|
|